Your browser doesn't support javascript.
loading
Liver-Unrelated Comorbid Conditions Do Not Affect Cognitive Performance or Hepatic Encephalopathy Progression in Cirrhosis.
Acharya, Chathur; Nadhem, Omar; Shaw, Jawaid; Hassouneh, Ramzi; Fagan, Andrew; McGeorge, Sara; Sterling, Richard K; Puri, Puneet; Fuchs, Michael; Luketic, Velimir; Sanyal, Arun J; Wade, James B; Gilles, HoChong S; Heuman, Douglas M; Tinsley, Felicia; Matherly, Scott; Lee, Hannah; Siddiqui, Mohammad S; Thacker, Leroy R; Bajaj, Jasmohan S.
Afiliação
  • Acharya C; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Nadhem O; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Shaw J; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Hassouneh R; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Fagan A; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • McGeorge S; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Sterling RK; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Puri P; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Fuchs M; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Luketic V; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Sanyal AJ; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Wade JB; Department of Psychiatry, VCU, Richmond, Virginia, USA.
  • Gilles HS; Department of Biostatistics, VCU, Richmond, Virginia, USA.
  • Heuman DM; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Tinsley F; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Matherly S; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Lee H; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Siddiqui MS; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
  • Thacker LR; Department of Biostatistics, VCU, Richmond, Virginia, USA.
  • Bajaj JS; Department of Gastroenterology Hepatology and Nutrition, VCU Medical Center and Central Virginia VA Healthcare System, Richmond, Virginia, USA.
Am J Gastroenterol ; 116(12): 2385-2389, 2021 12 01.
Article em En | MEDLINE | ID: mdl-34140445
ABSTRACT

INTRODUCTION:

We aimed to determine the effect of comorbidities on covert hepatic encephalopathy (CHE) diagnosis and overt hepatic encephalopathy (OHE) development.

METHODS:

Cirrhotic outpatients underwent CHE testing and 2-year follow-up. Cox regression was performed for time to OHE. In total, 700 patients (60 years, 84% men, model for end-stage liver disease 11) and 33% prior OHE underwent testing and follow-up.

RESULTS:

Major comorbidities were hypertension (54%), diabetes (35%), and depression (29%). Common medications were proton pump inhibitor (49%), beta-blockers (32%), and opioids (21%). Approximately 90 (40%) prior-OHE patients developed recurrence 93 (30,206) days post-testing predicted only by liverrelated variables.

DISCUSSION:

Demographics, cirrhosis characteristics, and opioid use, but not other comorbid conditions, were associated with CHE diagnosis and OHE progression.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicometria / Encefalopatia Hepática / Cognição / Cirrose Hepática Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicometria / Encefalopatia Hepática / Cognição / Cirrose Hepática Idioma: En Ano de publicação: 2021 Tipo de documento: Article